Statement Of Financial Position [Abstract]

OSE Immunotherapeutics - Filing #2816794

Concept	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2021-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2020-12-31	As at 2019-12-31	As at 2019-12-31	As at 2019-12-31	As at 2019-12-31	As at 2019-12-31	As at 2019-12-31
Statement of financial position [abstract]
Assets [abstract]
Property, plant and equipment	—	926,000 EUR	—	—	—	—	947,000 EUR	—	—	—	—	—	—	—	—	—	—	—
Intangible assets other than goodwill	—	51 122 EUR	—	—	—	—	52 600 EUR	—	—	—	—	—	—	—	—	—	—	—
Deferred tax assets	—	173,000 EUR	—	—	—	—	165,000 EUR	—	—	—	—	—	—	—	—	—	—	—
Cash and cash equivalents	—	33 579 EUR	—	—	—	—	29 368 EUR	—	—	—	—	—	25 842 EUR	—	—	—	—	—
Assets	—	101 876 EUR	—	—	—	—	96 973 EUR	—	—	—	—	—	—	—	—	—	—	—
Equity and liabilities [abstract]
Equity [abstract]
Issued capital	—	3 705 EUR	—	—	—	—	3 597 EUR	—	—	—	—	—	—	—	—	—	—	—
Share premium	—	65 605 EUR	—	—	—	—	65 449 EUR	—	—	—	—	—	—	—	—	—	—	—
Treasury shares	—	160,000 EUR	—	—	—	—	93,000 EUR	—	—	—	—	—	—	—	—	—	—	—
Equity	160,000 EUR	47 890 EUR	65 605 EUR	150,000 EUR	3 705 EUR	21 111 EUR	61 364 EUR	3 597 EUR	7 485 EUR	93,000 EUR	104,000 EUR	65 449 EUR	58 536 EUR	100,000 EUR	48 497 EUR	7 286 EUR	148,000 EUR	3 001 EUR
Liabilities [abstract]
Deferred tax liabilities	—	1 748 EUR	—	—	—	—	2 080 EUR	—	—	—	—	—	—	—	—	—	—	—
Equity and liabilities	—	101 876 EUR	—	—	—	—	96 973 EUR	—	—	—	—	—	—	—	—	—	—	—